Gibraltar Capital Management Inc. boosted its stake in Allergan PLC. (NYSE:AGN) by 3.4% during the second quarter, Holdings Channel reports. The fund owned 27,056 shares of the company’s stock after buying an additional 891 shares during the period. Allergan PLC. makes up about 6.6% of Gibraltar Capital Management Inc.’s holdings, making the stock its 6th largest position. Gibraltar Capital Management Inc.’s holdings in Allergan PLC. were worth $6,577,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Capital Investment Advisors LLC boosted its position in Allergan PLC. by 1.0% in the first quarter. Capital Investment Advisors LLC now owns 6,342 shares of the company’s stock valued at $1,515,000 after buying an additional 60 shares in the last quarter. Benson Investment Management Company Inc. boosted its position in Allergan PLC. by 1.3% in the first quarter. Benson Investment Management Company Inc. now owns 8,779 shares of the company’s stock valued at $2,097,000 after buying an additional 110 shares in the last quarter. Telemus Capital LLC boosted its position in Allergan PLC. by 208.1% in the first quarter. Telemus Capital LLC now owns 21,012 shares of the company’s stock valued at $5,020,000 after buying an additional 14,193 shares in the last quarter. Farmers & Merchants Investments Inc. boosted its position in Allergan PLC. by 89.9% in the first quarter. Farmers & Merchants Investments Inc. now owns 29,073 shares of the company’s stock valued at $6,946,000 after buying an additional 13,765 shares in the last quarter. Finally, Reliance Trust Co. of Delaware boosted its position in Allergan PLC. by 1.2% in the first quarter. Reliance Trust Co. of Delaware now owns 13,292 shares of the company’s stock valued at $3,176,000 after buying an additional 159 shares in the last quarter. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Allergan PLC. (AGN) traded down 0.47% on Wednesday, hitting $229.35. 1,688,171 shares of the stock were exchanged. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80. The firm has a market capitalization of $76.67 billion, a PE ratio of 6.99 and a beta of 1.16. The company has a 50-day moving average price of $245.03 and a 200-day moving average price of $238.77.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same quarter in the previous year, the company earned $3.35 EPS. The business’s revenue was up 8.8% on a year-over-year basis. Equities research analysts expect that Allergan PLC. will post $16.27 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be paid a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.21%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio (DPR) is 9.95%.

ILLEGAL ACTIVITY WARNING: “Allergan PLC. (AGN) Stake Increased by Gibraltar Capital Management Inc.” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/allergan-plc-agn-stake-increased-by-gibraltar-capital-management-inc-2/1496276.html.

AGN has been the topic of several recent analyst reports. Cowen and Company set a $400.00 target price on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Thursday, June 8th. Sanford C. Bernstein reissued an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. Mizuho cut their target price on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating on the stock in a research note on Friday, June 9th. Cantor Fitzgerald initiated coverage on shares of Allergan PLC. in a research note on Friday, June 16th. They set a “neutral” rating and a $231.00 target price on the stock. Finally, Zacks Investment Research raised shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 target price on the stock in a research note on Tuesday, July 11th. Eight investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $275.49.

In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.36% of the stock is owned by insiders.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.